Further, this study demonstrated that inhibiting estrogen signalling with the selective estrogen receptor downregulator (SERD) fulvestrant reduces tumor growth by enhancing the presence of activated CD8+ T cells in the TME, improving the efficacy of ICIs [129]. This evidence concerns the gene CD8A and neoplasm.